Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and if it is accurately predicted ...
3D bio-printed liver model and high-content imaging for evaluating the toxicity effects of compounds
The effectiveness of non-clinical drug safety predictions is enhanced by the adoption of three-dimensional (3D) cellular models. 3D bioprinting enables the generation of complex models with spatial ...
Massachusetts Institute of Technology (MIT), engineers developed a new liver tissue model to help reveal the stages of liver regeneration in hopes to help those individuals with liver disease, ...
As chronic liver disease becomes more widespread, researchers at Science Tokyo have developed a lab-grown organoid that replicates a regenerating liver, offering new hope for future treatments. The ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...
Please provide your email address to receive an email when new articles are posted on . TERN-501 6 mg, a thyroid hormone receptor beta agonist, reduced liver fat content in patients with nonalcoholic ...
Explore the latest findings in liver cirrhosis treatment to reduce liver damage and improve vascular function with new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback